Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.34 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.34 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | GPR3 | P46089 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30410319 | 0.94 | HTR2A (0.52) | HTR2AHTR7HTR2BGPR3ANPEP | |
| SCHEMBL353865 | 0.94 | HTR2A (0.52) | HTR2AHTR7HTR2BGPR3ANPEP | |
| SCHEMBL29444048 | 0.94 | HTR2A (0.52) | HTR2AHTR7HTR2BGPR3ANPEP | |
| Water SCHEMBL28455469 | 0.92 | HTR2A (0.50) | HTR2AHTR7HTR2BGPR3ANPEP | |
| Bromide SCHEMBL4922157 | 0.92 | HTR2A (0.50) | HTR2AHTR7HTR2BGPR3ANPEP | |
| Hydrochloric Acid SCHEMBL355946 | 0.92 | HTR2A (0.50) | HTR2AHTR7HTR2BGPR3ANPEP | |
| SCHEMBL22270015 | 0.92 | HTR2A (0.50) | HTR2AHTR7HTR2BGPR3ANPEP | |
| Biphenyl SCHEMBL21382703 | 0.84 | ALDH1A1 (0.45) | HTR2AHTR7HTR2BGPR3ALDH1A1 | |
| Dimethylamine SCHEMBL28473737 | 0.84 | HTR2A (0.44) | HTR2AHTR7HTR2BGPR3HDAC3 | |
| Trimethylammonium SCHEMBL27603581 | 0.82 | GPR3 (0.54) | HTR2AHTR7HTR2BGPR3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143211-B2 | Bioactive peptides | LYTIX BIOPHARMA AS (NO) | 2012-03-27 | — | — | US | disclosed |
| US-8048852-B2 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2011-11-01 | — | — | US | disclosed |
| EP-1263471-B1 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | LYTIX BIOPHARMA AS (NO) | 2011-10-12 | — | — | EP | disclosed |
| EP-2338522-A1 | Antitumoural therapies | Lytix Biopharma AS (NO) | 2011-06-29 | — | — | EP | disclosed |
| EP-1109827-B1 | BIOACTIVE PEPTIDES | LYTIX BIOPHARMA AS (NO) | 2011-06-22 | — | — | EP | disclosed |
| EP-1109831-B1 | CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | LYTIX BIOPHARMA AS (NO) | 2011-01-12 | — | — | EP | disclosed |
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| CN-101448797-A | Heterocyclic type cinnamamide derivative | EISAI R&D MAN CO LTD (JP) | 2009-06-03 | — | — | CN | disclosed |
| EP-2019094-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | CLIC4, NR3C2, MAN2B1 | ACHE 2838/4885CHRM2 565/4885CHRM1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.